See more : Cruzani, Inc. (CZNI) Income Statement Analysis – Financial Results
Complete financial analysis of Lukas Biomedical Inc. (6814.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lukas Biomedical Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- LAIX Inc. (LAIX) Income Statement Analysis – Financial Results
- Points.com Inc. (PCOM) Income Statement Analysis – Financial Results
- Liberty Latin America Ltd. (LILAB) Income Statement Analysis – Financial Results
- Shenzhen China Bicycle Company (Holdings) Limited (200017.SZ) Income Statement Analysis – Financial Results
- 3SBio Inc. (TRSBF) Income Statement Analysis – Financial Results
Lukas Biomedical Inc. (6814.TWO)
About Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the development of immune cell medical technology for regenerative medicine and auxiliary treatment of cancer in Taiwan. It operates through four divisions: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. The company also wholesales and retails cosmetics; and rents housing equipment. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 231.83M | 184.79M | 157.62M | 181.41M | 152.89M |
| Cost of Revenue | 97.94M | 86.88M | 61.56M | 62.96M | 52.73M |
| Gross Profit | 133.89M | 97.91M | 96.06M | 118.45M | 100.16M |
| Gross Profit Ratio | 57.75% | 52.98% | 60.95% | 65.29% | 65.51% |
| Research & Development | 77.33M | 55.92M | 54.98M | 35.39M | 29.20M |
| General & Administrative | 35.45M | 31.61M | 30.34M | 27.88M | 25.95M |
| Selling & Marketing | 64.67M | 58.95M | 55.00M | 61.85M | 52.08M |
| SG&A | 100.12M | 90.55M | 85.33M | 89.73M | 78.03M |
| Other Expenses | 0.00 | 1.39M | -397.00K | 140.00K | -17.00K |
| Operating Expenses | 177.45M | 146.48M | 140.31M | 125.11M | 107.23M |
| Cost & Expenses | 275.39M | 233.36M | 201.87M | 188.07M | 159.96M |
| Interest Income | 0.00 | 73.00K | 43.00K | 40.00K | 56.00K |
| Interest Expense | 0.00 | 2.92M | 4.42M | 4.83M | 5.19M |
| Depreciation & Amortization | 17.26M | 36.07M | 43.06M | 48.40M | 50.26M |
| EBITDA | -26.30M | -10.93M | -361.00K | 43.28M | 43.23M |
| EBITDA Ratio | -11.34% | -5.97% | -0.98% | 23.11% | 28.27% |
| Operating Income | -43.56M | -47.10M | -44.60M | -6.48M | -7.03M |
| Operating Income Ratio | -18.79% | -25.49% | -28.30% | -3.57% | -4.60% |
| Total Other Income/Expenses | -3.72M | -1.35M | -3.58M | -3.48M | -761.00K |
| Income Before Tax | -47.28M | -49.92M | -47.83M | -9.96M | -7.79M |
| Income Before Tax Ratio | -20.39% | -27.01% | -30.35% | -5.49% | -5.10% |
| Income Tax Expense | 78.00K | 151.00K | 1.66M | 586.00K | -802.00K |
| Net Income | -47.35M | -50.07M | -49.49M | -10.54M | -6.99M |
| Net Income Ratio | -20.43% | -27.10% | -31.40% | -5.81% | -4.57% |
| EPS | -1.28 | -1.35 | -1.50 | -0.32 | -0.20 |
| EPS Diluted | -1.28 | -1.35 | -1.50 | -0.32 | -0.20 |
| Weighted Avg Shares Out | 36.87M | 37.01M | 33.08M | 33.08M | 34.10M |
| Weighted Avg Shares Out (Dil) | 36.87M | 37.01M | 33.08M | 33.08M | 34.10M |
Source: https://incomestatements.info
Category: Stock Reports